A61K 2035/122
For inducing tolerance or supression of immune responses
Official title: {for inducing tolerance or supression of immune responses}
A61K2035/122 (For inducing tolerance or supression of immune responses) appears on 470 US grants and 917 published applications in this corpus.
Search patents in A61K- Granted patents
- 470
- Published applications
- 917
- Assignees
- 421
- Inventors
- 1,321
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 11 | 0 |
| 1999 | 8 | 0 |
| 2000 | 10 | 0 |
| 2001 | 17 | 11 |
| 2002 | 13 | 34 |
| 2003 | 13 | 37 |
| 2004 | 11 | 36 |
| 2005 | 6 | 35 |
| 2006 | 7 | 29 |
| 2007 | 4 | 26 |
| 2008 | 10 | 29 |
| 2009 | 14 | 38 |
| 2010 | 12 | 45 |
| 2011 | 21 | 43 |
| 2012 | 16 | 47 |
| 2013 | 17 | 43 |
| 2014 | 20 | 37 |
| 2015 | 21 | 49 |
| 2016 | 23 | 45 |
| 2017 | 15 | 37 |
| 2018 | 33 | 50 |
| 2019 | 14 | 46 |
| 2020 | 22 | 43 |
| 2021 | 36 | 39 |
| 2022 | 19 | 34 |
| 2023 | 24 | 21 |
| 2024 | 17 | 30 |
| 2025 | 21 | 20 |
| 2026 | 6 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating an immune disorder-related disease by reducing autoreactivity in a T cell compartment9 Jun 2026US 12,649,905 B2Hackensack University Medical Center
- Method for determining the risk to develop type 1 diabetes5 May 2026US 12,620,489 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Combinations for antigen based therapy21 Apr 2026US 12,605,432 B2Diamyd Medical AB
- Compositions and methods for treatment of liquid cancers7 Apr 2026US 12,594,301 B2Beam Therapeutics Inc.
- Method for obtaining regulatory T cells derived from thymic tissue and use of said cells as cell immunotherapy in immune system disorders17 Mar 2026US 12,577,533 B2Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
- Cells expressing parathyroid hormone 1 receptor and uses thereof24 Sep 2026US 2026/0286293 A1Tithon Biotech Inc.
- Cells expressing parathyroid hormone 1 receptor and uses thereof17 Sep 2026US 2026/0275277 A1Tithon Biotech Inc.
- Method for suppressing immune responses to transplanted cells, tissues and organs20 Aug 2026US 2026/0240909 A1
- Method for obtaining regulatory t cells derived from thymic tissue and use of said cells as cell immunotherapy in immune system disorders20 Aug 2026US 2026/0242733 A1Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
- Tuning expression for immune or cancer therapies13 Aug 2026US 2026/0232730 A1The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of J. David
Most cited
By later US patents
- Method for improving autologous transplantation264US 5,199,942 AImmunex Corporation · 1993
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Mesenchymal stem cells for prevention and treatment of immune responses in transplantation181US 6,328,960 B1Osiris Therapeutics, Inc. · 2001
- Human pancreatic epithelial progenitor cells and methods of isolation and use thereof171US 6,436,704 B1Raven Biotechnologies, Inc. · 2002
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001